Alan Lumsden MD to Join Endovasc's Scientific Advisory Committee.

MONTGOMERY, Texas -- Endovasc Inc. (OTCBB: EVSC), an early-stage drug development company that pioneers new cardiovascular and metabolic drug therapies, is pleased to announce that Alan B. Lumsden MD has accepted a position on the Company's Scientific Advisory Committee. Dr. Lumsden is currently Chief of the Division of Vascular Surgery in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine in Houston, Texas. Previously, Dr. Lumsden served as Chief of General Vascular Surgery at the Emory University School of Medicine in Atlanta, GA.

At Baylor, Dr. Lumsden splits his time between managing his practice as Chief of Vascular and Endovascular surgery and directing a team of doctors, nurses, and technicians, to perform innovative clinical studies that incorporate new technologies to study, diagnose, and improve treatments for vascular disease. He has contributed more than 200 articles to scholarly and professional journals; authored or co-authored 29 book chapters; participated in 40 scientific exhibitions; and made 171 presentations to professional audiences. His subjects have included the study and treatments of aortic aneurysms, endovascular surgery in kidneys, cardiovascular disease, and vascular and endoscopic vascular surgery.

"Management is delighted with the Advisory Committee's latest addition in Dr. Lumsden. He continues to be a pioneer in the vascular field as is demonstrated by his latest endeavor of leading clinical trials of a new synthetic liquid sealant to be used for vascular graft surgery," commented Dr. Diane Dottavio, President and Chief Executive Officer of Endovasc. "Endovasc believes that Dr. Lumsden's expertise in vascular and endovascular surgery will greatly assist the Company's efforts in developing treatments and medical devices to treat vascular dysfunction and heart disease."

About Endovasc, Inc.

Endovasc, Inc., established in 1996, is a Business Development Company focused on innovative drug development in the areas of cardiovascular and metabolic medicine. Endovasc's Subsidiaries include: Angiogenix Limited which retains the sublicense for an isomer of nicotine that has shown to recruit the body's own stem cells that help grow new blood vessels, aiming to relieve chest pain and improve heart function in patients with chronic myocardial ischemia; Liprostin Incorporated, which holds the intellectual property for a liposomal based treatment to increase circulation, and reduce leg pain in patients suffering from vascular disease; and Nutraceutical Development Corporation which has an agreement in place with an innovative product development company to commercialize its muscle mass enhancing product. For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor Statement

All statements other than statements of historical fact included in this press release are ``forward-looking statements.'' The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.